Atlas Trials

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Clinical trial NCT04017546 · COMPLETED

Trial details

NCT number
NCT04017546
Sponsor
Cyclacel Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
AMLMDS
Start date
2019-08-02
Primary completion
2022-11-15
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.